{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:06:51Z","timestamp":1791389211464,"version":"4.3.3"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Autosomal dominant hyper-IgE syndrome (AD-HIES) caused by dominant negative (DN) variants in the signal transducer and activator of transcription 3 gene (<jats:italic>STAT3<\/jats:italic>) is characterized by recurrent Staphylococcal abscesses, severe eczema, chronic mucocutaneous candidiasis (CMC), and non-immunological facial and skeletal features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe our experience with the diagnosis and treatment of adult patients with AD-HIES induced by DN-<jats:italic>STAT3<\/jats:italic> variants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The medical records of adult patients (&amp;gt;18 years) treated at the Allergy and Clinical Immunology Clinic of Hadassah Medical Center, Jerusalem, Israel, were retrospectively analyzed. Immune and genetic workups were used to confirm diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three adult patients (2 males; age 29-41 years) were diagnosed with DN-<jats:italic>STAT3<\/jats:italic> variants. All patients had non-immunological features, including coarse faces and osteopenia. Serious bacterial infections were noted in all patients, including recurrent abscesses, recurrent pneumonia, and bronchiectasis. CMC and diffuse dermatophytosis were noted in two patients. Two patients had severe atopic dermatitis refractory to topical steroids and phototherapy. Immune workup revealed elevated IgE in three patients and eosinophilia in two patients. Whole exome sequencing revealed DN-<jats:italic>STAT3<\/jats:italic> variants (c.1166C&amp;gt;T; p.Thr389Ile in two patients and c.1268G&amp;gt;A; p. Arg423Gln in one patient). Variants were located in DNA-binding domain (DBD) and did not hamper STAT3 phosphorylation Treatment included antimicrobial prophylaxis with trimethoprim\/sulfamethoxazole (n=2) and amoxycillin-clavulanic acid (n=1), and anti-fungal treatment with fluconazole (n=2) and voriconazole (n=1). Two patients who had severe atopic dermatitis, were treated with dupilumab with complete resolution of their rash. No adverse responses were noted in the dupilumab-treated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Dupilumab can be used safely as a biotherapy for atopic dermatitis in these patients as it can effectively alleviate eczema-related symptoms. Immunologists and dermatologists treating AD-HIES adult patients should be aware of demodicosis as a possible manifestation. DN-<jats:italic>STAT3<\/jats:italic> variants in DBD do not hamper STAT3 phosphorylation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.1044933","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T05:58:50Z","timestamp":1671515930000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience"],"prefix":"10.3389","volume":"13","author":[{"given":"Oded","family":"Shamriz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limor","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos J.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atar","family":"Lev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ortal","family":"Barel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raz","family":"Somech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Korem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Matza Porges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben Zion","family":"Garty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Nahum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Molho Pessach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Tal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"B1","first-page":"239","volume-title":"Pillai shiv chapter 10- differntiation and functions of CD4+ effector T cells, cellular and molecular immunology","author":"Abbass","year":"2018"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06096","article-title":"Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome","volume":"448","author":"Minegishi","year":"2007","journal-title":"Nature"},{"key":"B3","article-title":"STAT3 hyper IgE syndrome","author":"Hsu","year":"1993"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091706","article-title":"B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans","volume":"207","author":"Avery","year":"2010","journal-title":"J Exp Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2500\/ar.2012.3.0035","article-title":"Signal transducer and activator of transcription 3 mutation with invasive eosinophilic disease","volume":"3","author":"Crosby","year":"2012","journal-title":"Allergy Rhinol (Providence)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJM199903043400904","article-title":"Hyper-IgE syndrome with recurrent infections\u2013an autosomal dominant multisystem disorder","volume":"340","author":"Grimbacher","year":"1999","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/CIRCGENETICS.111.961235","article-title":"Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency","volume":"5","author":"Chandesris","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.11.042","article-title":"Benralizumab for prednisone-dependent eosinophilic asthma associated with novel STAT3 loss of function mutation","volume":"159","author":"Adatia","year":"2021","journal-title":"Chest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.835257","article-title":"Omalizumab for STAT3 hyper-IgE syndromes in adulthood: A case report and literature review","volume":"9","author":"Lan","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15072","article-title":"Clearance of atypical cutaneous manifestations of hyper-IgE syndrome with dupilumab","volume":"39","author":"Nihal","year":"2022","journal-title":"Pediatr Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-050351","article-title":"Dupilumab for STAT3-Hyper-IgE syndrome with refractory intestinal complication","volume":"148","author":"Lu","year":"2021","journal-title":"Pediatrics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17889","article-title":"Dupilumab treatment of eczema in a child with STAT3 hyper-immunoglobulin e syndrome","volume":"36","author":"Wang","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jaip.2021.08.042","article-title":"Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome","volume":"10","author":"Staudacher","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13770","article-title":"Remission of eczema and recovery of Th1 polarization following treatment with dupilumab in STAT3 hyper IgE syndrome","volume":"33","author":"Matucci-Cerinic","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.049","article-title":"Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14-year-old boy with autosomal dominant hyper-IgE syndrome","volume":"9","author":"Dixit","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaip.2022.01.011","article-title":"Treatment of STAT3-deficient hyper-immunoglobulin e syndrome with monoclonal antibodies targeting allergic inflammation","volume":"10","author":"James","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"108452","DOI":"10.1016\/j.clim.2020.108452","article-title":"Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper-IgE syndrome","volume":"215","author":"Sogkas","year":"2020","journal-title":"Clin Immunol"},{"key":"B18","volume-title":"Clinical review report: Dupilumab (Dupixent): (Sanofi-aventis Canada inc.): Indication: Moderate-to-severe atopic dermatitis (AD)","year":"2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/cei.13636","article-title":"Chronic demodicosis in patients with immune dysregulation: An unexpected infectious manifestation of signal transducer and activator of transcription (STAT)1 gain-of-function","volume":"206","author":"Shamriz","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/0022-2836(81)90087-5","article-title":"Identification of common molecular subsequences","volume":"147","author":"Smith","year":"1981","journal-title":"J Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/201178","article-title":"Scaling accurate genetic variant discovery to tens of thousands of samples","author":"Poplin","year":"2017","journal-title":"bioRxiv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1207.3907","article-title":"Haplotype-based variant detection from short-read sequencing","author":"MGG","year":"2012","journal-title":"arXiv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx019","article-title":"Robust and rapid algorithms facilitate large-scale whole genome sequencing downstream analysis in an integrative framework","volume":"45","author":"Li","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jaci.2009.10.059","article-title":"Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome","volume":"125","author":"Woellner","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-013-9895-0","article-title":"Reduced bone density in patients with autosomal dominant hyper-IgE syndrome","volume":"33","author":"Scheuerman","year":"2013","journal-title":"J Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073687","article-title":"STAT3 mutations in the hyper-IgE syndrome","volume":"357","author":"Holland","year":"2007","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202592","article-title":"Human STAT3 variants underlie autosomal dominant hyper-IgE syndrome by negative dominance","volume":"218","author":"Asano","year":"2021","journal-title":"J Exp Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108988","DOI":"10.1016\/j.clim.2022.108988","article-title":"Hyper IgE syndromes: A clinical approach","volume":"237","author":"Gharehzadehshirazi","year":"2022","journal-title":"Clin Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01051-1","article-title":"STAT3 hyper-IgE syndrome-an update and unanswered questions","volume":"41","author":"Tsilifis","year":"2021","journal-title":"J Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101306","DOI":"10.1016\/j.mycmed.2022.101306","article-title":"Multidrug resistant tinea corporis\/cruris: Response to voriconazole","volume":"32","author":"Khurana","year":"2022","journal-title":"J Mycol Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2018.08.003","article-title":"Update on advances in hematopoietic cell transplantation for primary immunodeficiency disorders","volume":"39","author":"Shamriz","year":"2019","journal-title":"Immunol Allergy Clin North Am"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.038","article-title":"Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism","volume":"131","author":"Hsu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.760019","article-title":"Case report: A new gain-of-Function mutation of STAT1 identified in a patient with chronic mucocutaneous candidiasis and rosacea-like demodicosis: An emerging association","volume":"12","author":"Martinot","year":"2021","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s10875-020-00942-z","article-title":"Pediatric demodicosis associated with gain-of-Function variant in STAT1 presenting as rosacea-type rash","volume":"41","author":"Baghad","year":"2021","journal-title":"J Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14011","article-title":"STAT1 gain-of-function and chronic demodicosis","volume":"37","author":"Molho-Pessach","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001343","article-title":"STAT1-activating cytokines limit Th17 responses through both T-bet-dependent and -independent mechanisms","volume":"185","author":"Villarino","year":"2010","journal-title":"J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2120469","article-title":"The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis","volume":"15","author":"Zhou","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15955","article-title":"Treatment options for DOCK8 deficiency-related severe dermatitis","volume":"48","author":"Ollech","year":"2021","journal-title":"J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.878989","article-title":"Hyper-IgE and carcinoma in CADINS disease","volume":"13","author":"Pietzsch","year":"2022","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01157-6","article-title":"A case of two adult brothers with wiskott-Aldrich syndrome, one treated with gene therapy and one with HLA-identical hematopoietic stem cell transplantation","volume":"42","author":"Consiglieri","year":"2022","journal-title":"J Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3954","article-title":"Dupilumab for severe generalized eczematous eruption complicating common variable immunodeficiency","volume":"31","author":"Votquenne","year":"2021","journal-title":"Eur J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jdcr.2020.12.004","article-title":"Refractory pruritus responds to dupilumab in a patient with TTC7A mutation","volume":"8","author":"Alipour Tehrany","year":"2021","journal-title":"JAAD Case Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.07.026","article-title":"Successful treatment of atopic dermatitis with dupilumab in the setting of X-linked agammaglobulinemia","volume":"10","author":"Fan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.06.020","article-title":"Successful use of dupilumab to treat eczema in a child with X-linked agammaglobulinemia","volume":"129","author":"Atwal","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2022.4288","article-title":"Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia","volume":"32","author":"Fujishima","year":"2022","journal-title":"Eur J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1044933\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T05:58:54Z","timestamp":1671515934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1044933\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2022.1044933"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1044933","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"article-number":"1044933"}}